DIGITAL EDITION

ARCHIVES

CURRENT ISSUE

Longitudinal Data in Patients with Niemann-Pick Type C Disease Under Combined High Intrathecal and Low Intravenous Dose of 2-hydroxylpropyl-β-cyclodextrin

by Evangelia Bountouvi, MD, PhD; Melpomeni Giorgi, MD; Anna Papadopoulou, PhD; Kaj Blennow, PhD; Ingemar Björkhem, PhD; Maria Tsirouda, PhD; Spyridon Kanellakis, Msc, PhD; Andreas Fryganas, MD; Maria Spanou, MD;

Catatonia in a 6-year-old Patient Following Disseminated Group A Streptococcus Infection

by Philip B Cawkwell, MD; Ivan Daniel Mayor, BA; and Richard J. Shaw,MD Drs. Cawkwell and Shaw and Mr. Mayor are with the Department of Psychiatry and Behavioral Sciences, Division

Blood–Brain Barrier: COVID-19, Pandemics, and Cytokine Norms

by Atmaram Yarlagadda, MD; Samuel L. Preston, DO; Rachel P. Jeyadhas, MD; Adam Edward Lang, PharmD; Rasha Hammamieh, PhD; And Anita H. Clayton, MD Dr. Yarlagadda is the Installation Director

Drug Development for Mental Illness: How Psychiatry Clinical Trial Sites are Meeting the Challenge of the COVID-19 Pandemic

by Robert E. Litman, MD; Peter Sorantin, PhD; and Elia E. Acevedo-Diaz, MD Drs. Litman is with CBH Health, Georgetown University Medical School in Washington, DC. Dr. Sorantin is with